IL205283A0 - Spiro - ring compound and use thereof for medical purposes - Google Patents
Spiro - ring compound and use thereof for medical purposesInfo
- Publication number
- IL205283A0 IL205283A0 IL205283A IL20528310A IL205283A0 IL 205283 A0 IL205283 A0 IL 205283A0 IL 205283 A IL205283 A IL 205283A IL 20528310 A IL20528310 A IL 20528310A IL 205283 A0 IL205283 A0 IL 205283A0
- Authority
- IL
- Israel
- Prior art keywords
- spiro
- ring compound
- medical purposes
- medical
- purposes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007279697 | 2007-10-26 | ||
US182307P | 2007-11-05 | 2007-11-05 | |
PCT/JP2008/069296 WO2009054479A1 (en) | 2007-10-26 | 2008-10-24 | Spiro-ring compound and use thereof for medical purposes |
Publications (2)
Publication Number | Publication Date |
---|---|
IL205283A0 true IL205283A0 (en) | 2010-12-30 |
IL205283A IL205283A (en) | 2014-06-30 |
Family
ID=40579581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL205283A IL205283A (en) | 2007-10-26 | 2010-04-22 | Spiro - ring compound and use thereof for medical purposes |
Country Status (30)
Country | Link |
---|---|
US (3) | US8299296B2 (en) |
EP (3) | EP2684861A3 (en) |
JP (5) | JP4568779B2 (en) |
KR (1) | KR101565622B1 (en) |
CN (1) | CN101835737B (en) |
AR (1) | AR071055A1 (en) |
AU (1) | AU2008314933B2 (en) |
BR (1) | BRPI0818687A2 (en) |
CA (1) | CA2704013C (en) |
CL (1) | CL2008003153A1 (en) |
CO (1) | CO6321230A2 (en) |
CY (1) | CY1113352T1 (en) |
DK (1) | DK2202216T3 (en) |
ES (1) | ES2386596T3 (en) |
HK (1) | HK1144421A1 (en) |
HR (1) | HRP20120696T1 (en) |
IL (1) | IL205283A (en) |
ME (1) | ME02338B (en) |
MX (1) | MX2010004435A (en) |
MY (1) | MY148469A (en) |
NZ (1) | NZ584161A (en) |
PE (1) | PE20091014A1 (en) |
PL (1) | PL2202216T3 (en) |
PT (1) | PT2202216E (en) |
RS (1) | RS52474B (en) |
RU (1) | RU2490250C2 (en) |
SI (1) | SI2202216T1 (en) |
TW (1) | TWI421070B (en) |
WO (1) | WO2009054479A1 (en) |
ZA (1) | ZA201002305B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5410417B2 (en) * | 2007-06-11 | 2014-02-05 | ジボダン エス エー | Organic compounds |
KR101565622B1 (en) * | 2007-10-26 | 2015-11-03 | 니뽄 다바코 산교 가부시키가이샤 | Spiro-ring compound and use thereof for medical purposes |
MX2010014571A (en) * | 2008-06-25 | 2011-03-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound. |
CA2765610A1 (en) * | 2009-06-29 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 3,3,5,5-tetramethylcyclohexanone |
WO2011000538A1 (en) * | 2009-06-29 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing neramexane |
EP2448911A1 (en) | 2009-06-29 | 2012-05-09 | Merz Pharma GmbH & Co. KGaA | Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane |
EP2289881A1 (en) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Method for stereoselective synthesis of bicyclical heterocycles |
AR078522A1 (en) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | SPIROPIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES AND INTERMEDIARY COMPOUND FOR SYNTHESIS |
AR078948A1 (en) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES |
WO2011078371A1 (en) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisothiazole derivative |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9040525B2 (en) | 2010-10-08 | 2015-05-26 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
JP2014504619A (en) | 2011-02-01 | 2014-02-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 9- [4- (3-Chloro-2-fluoro-phenylamino) -7-methoxy-quinazolin-6-yloxy] -1,4-diaza-spiro [5.5] undecan-5-onedimaleate, Use as a medicine and method for producing the same |
AR085990A1 (en) | 2011-04-27 | 2013-11-13 | Mochida Pharm Co Ltd | 1-OXIDE DERIVATIVES OF 3-HYDROXYISOTIAZOL USEFUL IN THE TREATMENT OF PHARMACEUTICAL DIABETES AND COMPOSITIONS CONTAINING THEM |
JPWO2012147516A1 (en) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | Cyclic amide derivative |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2875020B1 (en) | 2012-07-19 | 2017-09-06 | Boehringer Ingelheim International GmbH | Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one |
IN2015DN03795A (en) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
TWI692469B (en) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
US9133163B2 (en) | 2012-11-16 | 2015-09-15 | Bristol-Myers Squibb Company | Dihydropyrazole GPR40 modulators |
KR101569522B1 (en) | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, preparation method thereof, and pharmaceutical composition for use in preventing or treating metabolic diseases containing the same as an active ingredient |
WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
DK3107901T3 (en) | 2014-02-19 | 2020-06-22 | Piramal Entpr Ltd | RELATIONSHIPS FOR USE AS GPR120 AGONISTS |
US10273230B2 (en) | 2014-07-25 | 2019-04-30 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof |
CA2960757C (en) | 2014-09-11 | 2022-09-06 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
ES2805743T3 (en) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Method and pharmaceutical composition for use in the treatment of diabetes |
EP3604267A4 (en) * | 2017-03-31 | 2020-12-16 | Takeda Pharmaceutical Company Limited | Aromatic compound |
TWI707849B (en) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd-1/pd-l1 inhibitors |
TWI712412B (en) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd-1/pd-l1 inhibitors |
WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN112955435A (en) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | PD-1/PD-L1 inhibitors |
CA3156985A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
JP2023526625A (en) | 2020-05-19 | 2023-06-22 | キャリーオペ,インク. | AMPK Activator |
AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
CN115181023B (en) * | 2022-05-17 | 2023-07-28 | 东华理工大学 | Spiro active plasticizer and preparation method thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4331179A1 (en) * | 1993-09-14 | 1995-03-16 | Hoechst Schering Agrevo Gmbh | Substituted pyridines, processes for their preparation and their use as pesticides and fungicides |
RU2191007C2 (en) * | 1996-05-24 | 2002-10-20 | Лиганд Фармасьютикалз Инкорпорейтед | Method for treating niddm by rxr agonists |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
DE60315776T2 (en) * | 2002-10-14 | 2008-06-05 | Firmenich S.A. | Spiro compounds as perfumes |
JP4594611B2 (en) | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | Receptor function regulator |
AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US7820837B2 (en) * | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005051373A1 (en) * | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
JP4074616B2 (en) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3- (4-Benzyloxyphenyl) propanoic acid derivatives |
TW200523247A (en) * | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
ES2433466T3 (en) * | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic disorders |
JP4859665B2 (en) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | Alkoxyphenylpropanoic acid derivatives |
JP2007284350A (en) * | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | Therapeutic agent for diabetes |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US7582803B2 (en) * | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
EP2061760A1 (en) * | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
KR101565622B1 (en) * | 2007-10-26 | 2015-11-03 | 니뽄 다바코 산교 가부시키가이샤 | Spiro-ring compound and use thereof for medical purposes |
MX2010014571A (en) | 2008-06-25 | 2011-03-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound. |
-
2008
- 2008-10-24 KR KR1020107011427A patent/KR101565622B1/en not_active IP Right Cessation
- 2008-10-24 BR BRPI0818687A patent/BRPI0818687A2/en not_active IP Right Cessation
- 2008-10-24 EP EP13184140.5A patent/EP2684861A3/en not_active Withdrawn
- 2008-10-24 ES ES08841970T patent/ES2386596T3/en active Active
- 2008-10-24 ME MEP-2016-195A patent/ME02338B/en unknown
- 2008-10-24 WO PCT/JP2008/069296 patent/WO2009054479A1/en active Application Filing
- 2008-10-24 DK DK08841970.0T patent/DK2202216T3/en active
- 2008-10-24 CN CN2008801132388A patent/CN101835737B/en not_active Expired - Fee Related
- 2008-10-24 RU RU2010121160/04A patent/RU2490250C2/en not_active IP Right Cessation
- 2008-10-24 PT PT08841970T patent/PT2202216E/en unknown
- 2008-10-24 AR ARP080104642A patent/AR071055A1/en not_active Application Discontinuation
- 2008-10-24 PL PL08841970T patent/PL2202216T3/en unknown
- 2008-10-24 MY MYPI2010001866A patent/MY148469A/en unknown
- 2008-10-24 TW TW097140805A patent/TWI421070B/en not_active IP Right Cessation
- 2008-10-24 JP JP2008273676A patent/JP4568779B2/en active Active
- 2008-10-24 NZ NZ584161A patent/NZ584161A/en not_active IP Right Cessation
- 2008-10-24 US US12/258,033 patent/US8299296B2/en active Active
- 2008-10-24 PE PE2008001826A patent/PE20091014A1/en not_active Application Discontinuation
- 2008-10-24 CL CL2008003153A patent/CL2008003153A1/en unknown
- 2008-10-24 EP EP12173164A patent/EP2508503A1/en not_active Withdrawn
- 2008-10-24 AU AU2008314933A patent/AU2008314933B2/en not_active Ceased
- 2008-10-24 SI SI200830752T patent/SI2202216T1/en unknown
- 2008-10-24 EP EP08841970A patent/EP2202216B1/en active Active
- 2008-10-24 RS RS20120400A patent/RS52474B/en unknown
- 2008-10-24 MX MX2010004435A patent/MX2010004435A/en active IP Right Grant
- 2008-10-24 CA CA2704013A patent/CA2704013C/en not_active Expired - Fee Related
-
2010
- 2010-03-31 ZA ZA2010/02305A patent/ZA201002305B/en unknown
- 2010-04-22 IL IL205283A patent/IL205283A/en not_active IP Right Cessation
- 2010-05-26 CO CO10062839A patent/CO6321230A2/en active IP Right Grant
- 2010-07-23 JP JP2010165678A patent/JP2010270137A/en active Pending
- 2010-11-26 HK HK10110999.8A patent/HK1144421A1/en not_active IP Right Cessation
-
2012
- 2012-08-22 CY CY20121100753T patent/CY1113352T1/en unknown
- 2012-09-04 HR HRP20120696AT patent/HRP20120696T1/en unknown
- 2012-09-14 US US13/616,389 patent/US20130109710A1/en not_active Abandoned
-
2014
- 2014-08-04 JP JP2014158380A patent/JP2014221829A/en active Pending
- 2014-11-17 US US14/542,869 patent/US20150299090A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001396A patent/JP2016102130A/en not_active Ceased
-
2017
- 2017-03-14 JP JP2017049246A patent/JP2017132787A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1144421A1 (en) | Spiro-ring compound and use thereof for medical purposes | |
GB0701426D0 (en) | Compounds and their use | |
HK1125961A1 (en) | Preparation containing organosilicium compound and its use | |
GB0818241D0 (en) | Compounds and their use | |
EP2231087A4 (en) | Surgical tape | |
GB0803018D0 (en) | Therapeutic compounds and their use | |
IL208081A0 (en) | Amido - thiophene compounds and their use | |
EP2345629A4 (en) | Fluorene compound and use thereof for medical purposes | |
ZA201007395B (en) | Aryl-quinolyl compounds and their use | |
SI2344449T1 (en) | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | |
IL208771A0 (en) | Iminopyridine derivatives and use thereof | |
GB0817208D0 (en) | Therapeutic apsap compounds and their use | |
EP2170874A4 (en) | Novel compounds and their use | |
GB0718718D0 (en) | Compound and use thereof | |
EP2231163A4 (en) | Compounds and therapeutic use thereof | |
GB0812913D0 (en) | Therapeutic compounds and their use | |
GB0801319D0 (en) | Compounds and their use | |
GB0802128D0 (en) | Therapeutic compounds and their use | |
GB0815134D0 (en) | Therapeutic compounds and their use | |
GB0716122D0 (en) | New medical use | |
GB0718560D0 (en) | Compounds and their use | |
GB0701795D0 (en) | Compounds and their use | |
GB0718559D0 (en) | Compounds and their use | |
GB0702417D0 (en) | Compounds and their use | |
GB0718562D0 (en) | Compounds and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |